Business Context and Reporting Period
This Form 8-K filing by Catalyst Biosciences, Inc. (CBIO) reports on events occurring on June 18, 2020. The registrant is a biopharmaceutical company focused on developing therapies for autoimmune diseases. The filing details the entry into a material definitive agreement for a public offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 4,615,384 shares of common stock.
- Public Offering Price: $6.50 per share.
- Estimated Net Proceeds: Approximately $27.9 million (after underwriting discounts, commissions, and estimated expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 692,307 additional shares.
- Expected Closing Date: June 22, 2020.
The filing does not provide historical revenue, profit, cash flow, margin, or debt figures for the company.
Material Changes and Use of Proceeds
The primary material change is the execution of an underwriting agreement with Raymond James & Associates, Inc. The company intends to use the net proceeds for general corporate purposes, specifically including:
- Research and development activities for its component program.
- Clinical and manufacturing activities for MarzAA and DalcA.
- Other R&D activities, capital expenditures, and selling, general, and administrative costs.
- Facilities expansion and working capital needs.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance or forward-looking earnings projections. The transaction is subject to customary closing conditions. The Underwriting Agreement includes standard representations, warranties, market standoff provisions, and indemnification obligations. The company noted that the offering is being made pursuant to a shelf registration statement filed in December 2018.
Investor Verification Checklist
- Verify the final closing of the offering on or around June 22, 2020.
- Confirm whether the underwriters exercised the 30-day option to purchase the additional 692,307 shares.
- Review the full text of the Underwriting Agreement (Exhibit 1.1) for specific lock-up periods and indemnification terms.
- Monitor subsequent filings for the actual allocation of proceeds to the MarzAA and DalcA programs.